Prognostic Value of Downregulated 5-hydroxymethylcytosine Expression in Renal Cell Carcinoma: a 10 Year Follow-up Retrospective Study

Overview

Journal J Cancer

Specialty Oncology

Date 2020 Jan 21

PMID 31956367

Citations 6

Authors

Song Chen

Qiang Zhou

Tongzu Liu

Weibing Zhang

Xian-Tao Zeng

Zhongqiang Guo

Affiliations

Soon will be listed here.

Abstract

5-hydroxymethylcytosine (5hmC) is converted from DNA methylation of cytosine (5mC) by the catalysis of TET proteins, and proposed to be involved in tumorigenesis. However, the prognostic value of 5hmC in renal cell carcinoma (RCC) is still unclear. This study aimed to define the clinical significance of 5hmC in RCC. We performed dot blot assays to measure the relative expression of 5hmC in RCC. We reviewed the clinical records of 310 RCC patients and performed immunohistochemical (IHC) staining of 5hmC. The overall survival (OS) and cancer specific survival (CSS) of all patients were recorded over a 10-year follow-up period. Effective prognostic nomograms which contained 5hmC were established to provide individualized OS and CSS in RCC. 5hmC expression level was significantly decreased in RCC tissues compared with those in the normal counterparts. Kaplan-Meier curves revealed that high 5hmC expression had a good prognostic impact on RCC patients. Cox multivariate survival analyses further indicated 5hmC was an independent prognostic factor for RCC survival. Nomograms constructed based on cox regression analysis were available to calculate the survival probability directly. Calibration curves displayed good agreements. The findings were validated with an independent external cohort included 77 RCC cases. Thus, we believe we have found a significative prognostic factor for RCC.

Citing Articles

Optical genome and epigenome mapping of clear cell renal cell carcinoma.

Margalit S, Tulpova Z, Michaeli Y, Zur T, Deek J, Louzoun-Zada S NAR Cancer. 2025; 7(1):zcaf008.

PMID: 40061565 PMC: 11886815. DOI: 10.1093/narcan/zcaf008.

Ultrasensitive detection of 5-hydroxymethylcytosine in genomic DNA using a graphene-based sensor modified with biotin and gold nanoparticles.

Imran H, Lee H, Alam A, An J, Ko M, Lim S Mater Today Bio. 2024; 27:101123.

PMID: 38988817 PMC: 11234158. DOI: 10.1016/j.mtbio.2024.101123.

5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in Lung Cancer.

Shao J, Xu Y, Olsen R, Kasparian S, Sun K, Mathur S Cells. 2024; 13(8.

PMID: 38667328 PMC: 11049556. DOI: 10.3390/cells13080715.

Cell-Free DNA 5-Hydroxymethylcytosine Signatures for Lung Cancer Prognosis.

Shao J, Olsen R, Kasparian S, He C, Bernicker E, Li Z Cells. 2024; 13(4.

PMID: 38391911 PMC: 10886903. DOI: 10.3390/cells13040298.

Loss of 5-hydroxymethylcytosine as a Poor Prognostic Factor for Primary Testicular Diffuse Large B-cell Lymphoma.

Shen Y, Wang L, Ou J, Wang B, Cen X Int J Med Sci. 2022; 19(2):225-232.

PMID: 35165508 PMC: 8795795. DOI: 10.7150/ijms.65517.

References

Chen K, Zhang J, Guo Z, Ma Q, Xu Z, Zhou Y . Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer. Cell Res. 2015; 26(1):103-18. PMC: 4816137. DOI: 10.1038/cr.2015.150. View

Yang J, Guo R, Wang H, Ye X, Zhou Z, Dan J . Tet Enzymes Regulate Telomere Maintenance and Chromosomal Stability of Mouse ESCs. Cell Rep. 2016; 15(8):1809-21. DOI: 10.1016/j.celrep.2016.04.058. View

Kapitsinou P, Haase V . The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ. 2008; 15(4):650-9. PMC: 3799983. DOI: 10.1038/sj.cdd.4402313. View

Lu F, Liu Y, Jiang L, Yamaguchi S, Zhang Y . Role of Tet proteins in enhancer activity and telomere elongation. Genes Dev. 2014; 28(19):2103-19. PMC: 4180973. DOI: 10.1101/gad.248005.114. View

Motzer R, Bander N, Nanus D . Renal-cell carcinoma. N Engl J Med. 1996; 335(12):865-75. DOI: 10.1056/NEJM199609193351207. View

Kim W, Kaelin W . Role of VHL gene mutation in human cancer. J Clin Oncol. 2004; 22(24):4991-5004. DOI: 10.1200/JCO.2004.05.061. View

Jonasch E, Futreal P, Davis I, Bailey S, Kim W, Brugarolas J . State of the science: an update on renal cell carcinoma. Mol Cancer Res. 2012; 10(7):859-80. PMC: 3399969. DOI: 10.1158/1541-7786.MCR-12-0117. View

Nestor C, Ottaviano R, Reddington J, Sproul D, Reinhardt D, Dunican D . Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res. 2011; 22(3):467-77. PMC: 3290782. DOI: 10.1101/gr.126417.111. View

Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T . Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013; 45(8):860-7. DOI: 10.1038/ng.2699. View

10.

Rasmussen K, Helin K . Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 2016; 30(7):733-50. PMC: 4826392. DOI: 10.1101/gad.276568.115. View

11.

Liu M, Ohtani H, Zhou W, Orskov A, Charlet J, Zhang Y . Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine. Proc Natl Acad Sci U S A. 2016; 113(37):10238-44. PMC: 5027469. DOI: 10.1073/pnas.1612262113. View

12.

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

13.

Branco M, Ficz G, Reik W . Uncovering the role of 5-hydroxymethylcytosine in the epigenome. Nat Rev Genet. 2011; 13(1):7-13. DOI: 10.1038/nrg3080. View

14.

Petrozza V, Carbone A, Bellissimo T, Porta N, Palleschi G, Pastore A . Oncogenic MicroRNAs Characterization in Clear Cell Renal Cell Carcinoma. Int J Mol Sci. 2015; 16(12):29219-25. PMC: 4691105. DOI: 10.3390/ijms161226160. View

15.

Mubarak M, Kazi J, Mohsin R, Hashmi A, Naqvi S, Ul Hassan Rizvi S . Histopathology of surgically treated renal tumours in young adults: a developing country perspective. J Cancer Res Clin Oncol. 2011; 138(2):189-94. DOI: 10.1007/s00432-011-1082-1. View

16.

Shi X, Yu Y, Luo M, Zhang Z, Shi S, Feng X . Loss of 5-Hydroxymethylcytosine Is an Independent Unfavorable Prognostic Factor for Esophageal Squamous Cell Carcinoma. PLoS One. 2016; 11(4):e0153100. PMC: 4822830. DOI: 10.1371/journal.pone.0153100. View

17.

Zhang F, Liu Y, Zhang Z, Li J, Wan Y, Zhang L . 5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas. Sci Rep. 2016; 6:20882. PMC: 4749994. DOI: 10.1038/srep20882. View

18.

Thomson J, Ottaviano R, Unterberger E, Lempiainen H, Muller A, Terranova R . Loss of Tet1-Associated 5-Hydroxymethylcytosine Is Concomitant with Aberrant Promoter Hypermethylation in Liver Cancer. Cancer Res. 2016; 76(10):3097-108. PMC: 5021200. DOI: 10.1158/0008-5472.CAN-15-1910. View

19.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

20.

Bedke J, Heide J, Ribback S, Rausch S, de Martino M, Scharpf M . Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. BJU Int. 2017; 121(1):84-92. DOI: 10.1111/bju.13984. View